Form 4: RenovoRx Director Granted 47,640 Stock Options

RenovoRx Director K. Angela Macfarlane was granted 47,640 stock options with an exercise price of $1.34, vesting over 12 months.

Summary

• K. Angela Macfarlane, a Director of RenovoRx, Inc. (RNXT), reported the acquisition of stock options.
• The earliest transaction date for this grant was October 1, 2025.
• Macfarlane was granted 47,640 stock options, which have an exercise price of $1.34 per share.
• These options will vest in 12 equal monthly installments, with vesting commencing on November 1, 2025.
• The granted stock options have an expiration date of October 1, 2035.
• Following this reported transaction, Macfarlane directly beneficially owns 47,640 derivative securities.

Sentiment

Score: 7

Explanation: The grant of stock options to a director aligns their interests with those of shareholders, which is generally viewed positively as it incentivizes long-term performance. This is a routine compensation event.

Positives

• The grant of stock options to a director aligns their financial interests with those of the company's shareholders, incentivizing long-term performance and value creation.

Future Outlook

The vesting schedule indicates that the director's beneficial ownership of these shares will increase incrementally over the next 12 months, starting November 1, 2025, subject to continued service.

Industry Context

The grant of stock options is a common practice in the biotechnology and medical device industry for compensating directors and executives, aiming to align their incentives with company performance and shareholder value.

Stakeholder Impact

• Shareholders: The grant of options to a director can enhance alignment between management and shareholder interests, potentially leading to improved long-term performance.
• Employees: While this specific filing pertains to a director, equity grants are a common incentive across various levels, fostering a sense of ownership and commitment.

Next Steps

• The stock options will vest in 12 equal monthly installments beginning on November 1, 2025.

Key Dates

Keywords

RenovoRx, RNXT, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant